|
Jan 2
|
January 2025's Undervalued Small Caps With Insider Action On US Markets
|
|
Jan 1
|
Is There An Opportunity With Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) 26% Undervaluation?
|
|
Nov 11
|
Celldex Therapeutics to Present at Upcoming Investor Conferences
|
|
Nov 8
|
Celldex Therapeutics Third Quarter 2024 Earnings: Beats Expectations
|
|
Sep 26
|
CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study
|
|
Sep 25
|
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
|
|
Aug 8
|
Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 8
|
Celldex: Q2 Earnings Snapshot
|
|
Aug 8
|
Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
|
Jul 29
|
Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria
|
|
Jul 28
|
Companies Like Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Invest In Growth
|
|
Jun 11
|
Insider Sale: SVP, Chief Medical Officer Diane Young Sells 45,000 Shares of Celldex ...
|
|
May 15
|
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
|
|
May 9
|
Wall Street Analysts Believe Celldex (CLDX) Could Rally 67.77%: Here's is How to Trade
|
|
May 8
|
Celldex Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
|
May 6
|
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
Apr 17
|
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
|
|
Apr 9
|
Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
|
|
Apr 8
|
All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy
|
|
Apr 8
|
Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
|